(Q38643963)

5 September 2017

title

Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease (English)

1 reference

5 September 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

0 references

1

Jos Prickaerts

1 reference

5 September 2017

3

Arjan Blokland

1 reference

5 September 2017

2

Pim R A Heckman

1 reference

5 September 2017

language of work or name

English

0 references

publication date

3 August 2017

1 reference

Expert Opinion on Investigational Drugs

5 September 2017

published in

1 reference

5 September 2017

volume

26

1 reference

5 September 2017

issue

9

1 reference

5 September 2017

page(s)

1033-1048

1 reference

Creative Commons Attribution 4.0 International

5 September 2017

copyright license

start time

9 August 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterases in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The cholinergic hypothesis--ten years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Adamantane - A Lead Structure for Drugs in Clinical Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

PDE inhibition and cognition enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

PDE4 as a target for cognition enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Activity-dependent long-term enhancement of transmitter release by presynaptic 3',5'-cyclic GMP in cultured hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Structural basis for the design of selective phosphodiesterase 4B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

PDE4D inhibitors: a potential strategy for the treatment of memory impairment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Psychopharmacological effects of vinpocetine in normal healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cognitex supplementation in elderly adults with memory complaints: an uncontrolled open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The safety and lack of efficacy of vinpocetine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Denbufylline in dementia: a double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Sildenafil (Viagra): is there an influence on psychological performance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Pharmacokinetics and metabolism of vincamine and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

PDE2 inhibition: potential for the treatment of cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cilostazol prevents amyloid β peptide25‐35‐induced memory impairment and oxidative stress in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase genes and antidepressant treatment response: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Assessing the emetic potential of PDE4 inhibitors in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Effect of sildenafil (Viagra®) on cerebral blood flow velocity: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

A placebo-controlled study of sildenafil effects on cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive funct

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

PDE10A inhibitors: novel therapeutic drugs for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase 11A (PDE11A), Enriched in Ventral Hippocampus Neurons, is Required for Consolidation of Social but not Nonsocial Memories in Mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

PDE11A regulates social behaviors and is a key mechanism by which social experience sculpts the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Translational issues with the development of cognition enhancing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

The object pattern separation (OPS) task: a behavioral paradigm derived from the object recognition task

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Spatial discrimination deficits as a function of mnemonic interference in aged adults with and without memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Post-study caffeine administration enhances memory consolidation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

Cilostazol: a review of its use in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1364360

10.1080/13543784.2017.1364360

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference